← Leaderboards
Gregory R J Thatcher
University Of Arizona
$19,556,155
Attributed
$26,821,641
Total exposure
18
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,821,641 · 18
By mechanism
R01$8,320,194 · 5
RF1$5,600,624 · 2
U01$5,212,560 · 2
UH2$3,306,742 · 1
R21$1,891,675 · 5
R33$1,346,661 · 1
Top collaborators
- Mary Jo Ladu7 shared
- Pavel A Petukhov7 shared
- David Lee Williams5 shared
- Timothy A Marlowe2 shared
- David L. Mccormick2 shared
- Nanduri R Prabhakar2 shared
- Scott Thomas Brady1 shared
- Michael Jackson1 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Timothy A Marlowe$5,077,422
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposDesignIn VitroIn VivoAnimal ModelCellsBasePropertyLeadDosePharmaceutical PreparationsAttenuatedBiological AvailabilityProteinsMouse ModelPlasmaFutureLinkSafetyReportingOralCell LineClinical TrialsBiological Markers
Grant awards (55)
Small Molecule Ligands Targeting Pathological Tau Signaling In AD And Related Dementias$3,336,256
RF1 · FY2025 · AG
Nonlipogenic ABCA1 inducers for ADRD$728,720
U01 · FY2025 · AG · contact PI
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)$631,711
R01 · FY2025 · CA · contact PI
Nonlipogenic ABCA1 inducers for ADRD$751,598
U01 · FY2024 · AG · contact PI
Discovery of PPI inhibitors for the FAK FAT domain$170,433
R21 · FY2024 · CA
Nonlipogenic ABCA1 inducers for ADRD$755,497
U01 · FY2023 · AG · contact PI
Nonlipogenic ABCA1 inducers for ADRD - Supplement$373,042
U01 · FY2023 · AG · contact PI
Discovery of PPI inhibitors for the FAK FAT domain$215,284
R21 · FY2023 · CA
Nonlipogenic ABCA1 inducers for ADRD$756,926
U01 · FY2022 · AG · contact PI
Identification of preclinical drug candidates for the treatment of schistosomiasis$412,893
R33 · FY2021 · AI
Novel allosteric activation of nicotinamide rescue$2,264,368
RF1 · FY2020 · AG · contact PI
Estrogen therapy and APOE4 risk in Alzheimer's tested in female EFAD mice$635,706
R01 · FY2020 · AG
Identification of preclinical drug candidates for the treatment of schistosomiasis$443,078
R33 · FY2020 · AI
Estrogen therapy and APOE4 risk in Alzheimer's tested in female EFAD mice$591,148
R01 · FY2019 · AG · contact PI
Identification of preclinical drug candidates for the treatment of schistosomiasis$490,690
R33 · FY2019 · AI
R01 Estrogen therapy and APOE4 risk in Alzheimer's tested in female EFAD mice$70,750
R01 · FY2019 · AG · contact PI
Estrogen therapy and APOE4 risk in Alzheimer's tested in female EFAD mice$600,903
R01 · FY2018 · AG · contact PI
Identification of preclinical drug candidates for the treatment of schistosomiasis$169,545
R21 · FY2018 · AI
Nomethiazoles harnessing GABA and NO mimetic activity for Alzheimer's therapy$697,279
R42 · FY2017 · AG · contact PI
Estrogen therapy and APOE4 risk in Alzheimer's tested in female EFAD mice$578,095
R01 · FY2017 · AG · contact PI
Partial Agonists at Estrogen Receptor alpha for Breast Cancer Therapy$474,283
R01 · FY2017 · CA · contact PI
Identification of preclinical drug candidates for the treatment of schistosomiasis$222,045
R21 · FY2017 · AI
Partial Agonists at Estrogen Receptor alpha for Breast Cancer Therapy$476,663
R01 · FY2016 · CA · contact PI
Nomethiazoles harnessing GABA and NO mimetic activity for Alzheimer's therapy$296,059
R42 · FY2016 · AG · contact PI
Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing$1,643,080
UH2 · FY2015 · HL
Partial Agonists at Estrogen Receptor alpha for Breast Cancer Therapy$485,489
R01 · FY2015 · CA · contact PI
Biointeractions of Antiestrogens with Nitric Oxide$235,231
R01 · FY2015 · CA · contact PI
Potential ApoE Isoform-Specific Detrimental Effects of RXR Agonists in Alzheimer'$189,324
R21 · FY2015 · AG · contact PI
Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing$1,663,662
UH2 · FY2014 · HL
Potential ApoE Isoform-Specific Detrimental Effects of RXR Agonists in Alzheimer'$233,581
R21 · FY2014 · AG · contact PI
Biointeractions of Antiestrogens with Nitric Oxide$228,246
R01 · FY2014 · CA · contact PI
Biointeractions of Antiestrogens with Nitric Oxide$221,253
R01 · FY2013 · CA · contact PI
Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy$149,847
R41 · FY2013 · AG · contact PI
Nitric Oxide Chimera Drugs for Colon Cancer Chemoprevention$307,734
R01 · FY2012 · CA · contact PI
Biointeractions of Antiestrogens with Nitric Oxide$235,446
R01 · FY2012 · CA · contact PI
Harnessing GABA and NO mimetic activity for Alzheimer's therapy$346,128
U01 · FY2011 · AG · contact PI
Nitric Oxide Chimera Drugs for Colon Cancer Chemoprevention$307,975
R01 · FY2011 · CA · contact PI
Biointeractions of Antiestrogens with Nitric Oxide$234,855
R01 · FY2011 · CA · contact PI
Harnessing GABA and NO mimetic activity for Alzheimer's therapy$502,307
U01 · FY2010 · AG · contact PI
Nitric Oxide Chimera Drugs for Colon Cancer Chemoprevention$317,732
R01 · FY2010 · CA · contact PI
Harnessing GABA and NO mimetic activity for Alzheimer's therapy$492,780
U01 · FY2009 · AG · contact PI
Nitric Oxide Chimera Drugs for Colon Cancer Chemoprevention$317,976
R01 · FY2009 · CA · contact PI
Harnessing GABA and NO mimetic activity for Alzheimer's therapy$505,562
U01 · FY2008 · AG · contact PI
Nitric Oxide Chimera Drugs for Colon Cancer Chemoprevention$318,203
R01 · FY2008 · CA · contact PI
Biointeractions of antiestrogens with nitric oxide$229,652
R01 · FY2008 · CA · contact PI
Biointeractions of antiestrogens with nitric oxide$46,529
R01 · FY2008 · CA · contact PI
Biointeractions of antiestrogens with nitric oxide$229,652
R01 · FY2007 · CA · contact PI
Nitric oxide mimetic NSAIDs for treatment of Alzheimer's Disease$156,149
R21 · FY2007 · AG · contact PI
Biointeractions of antiestrogens with nitric oxide$46,529
R01 · FY2007 · CA · contact PI
Biointeractions of antiestrogens with nitric oxide$236,510
R01 · FY2006 · CA · contact PI
Botanicals for Treatment of Depression$185,024
R21 · FY2006 · AT · contact PI
Nitric oxide mimetic NSAIDs for treatment of Alzheimer's Disease$160,813
R21 · FY2006 · AG · contact PI
Biointeractions of antiestrogens with nitric oxide$19,721
R01 · FY2006 · CA · contact PI
Biointeractions of antiestrogens with nitric oxide$242,202
R01 · FY2005 · CA
Botanicals for Treatment of Depression$189,477
R21 · FY2005 · AT